Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Pakistan Society Of Chemical Pathologists Distance Learning Programme In Chemical Pathology (DLP-2) Lesson No 16 Metabolic Bone Disease By Dr Lena Jafri , FCPS MBBS Consultant Chemical Pathologist Aga Khan University Hospital Part I MCQs (One Best Type) Q.1: A 30 year old female complains of backache and generalized weakness. Her biochemical profile was as following : • Calcium: 7.5 mg/dl • Phosphorous: 2.2 mg/dl • Alkaline phosphatase : 107 U/l She is most likely suffering from: a. Hypomagnesaemia b. Hypoparathyroidism c. Osteitis fibrosa cystica d. Paget’s Disease e. Vitamin D deficiency e. Vitamin D deficiency Introduction: Vitamin D • Fat soluble hormone • Major forms are Vitamin D2 (ergocalciferol) and D3 (cholecalciferol) • Receptors have been identified for >30 tissues • Function of the immune, reproductive, muscular, skeletal and integumentary system • VDR best characterized on intestine, kidney and bone • Critical for maintenance of bone health Role of Calcitriol • Stimulates GI absorption of both calcium and phosphate • Stimulates renal reabsorption of both calcium and phosphate • Stimulates bone resorption Net effect of calcitriol ↑ serum calcium ↑ serum phosphate Sources and Metabolism of Vitamin D Daily need of Vitamin D • Exposure of arms & legs for 5-30 min (depending on time, season, latitude & skin pigmentation) between 10am3pm twice/week • With longer exposure to UVB rays, an equilibrium is achieved in the skin, and it degrades as fast as it is generated Serum Levels of 25 hydroxy vitamin D “deficiency” ng/ml 10 “Insufficiency” 20 “ Normal” 30 40 50 Hollick MF. NEJM. 2007; 266-280. Boonen S et al. Osteoporosis Int. 2004;15:511-519. Lips P. Endocr Rev. 2001;22:477-501. Heaney RP. Osteoporosi Int. 2000;11:553-555. Heaney RP. Am J Clin Nutr. 2004; 80 (suppl):1706S-1709S. Thomas MK. NEJM. 1998;388:777-781. Rickets and Osteomalacia Slides courtesy of Dr Mariam Rafiq, QAMC, Bwp Difference between Rickets and Osteomalacia Rickets : deficient mineralization at the growth plate • Disease of growing bone. • Refer to changes at the growth plate caused by deficient mineralization of bone. • Occurs before the growth plates fuse. Osteomalacia: impaired mineralization of the bone matrix • Rickets and osteomalacia usually occur together when growth plates are open only osteomalacia occurs after the growth plates have fused. Classification of Rickets Calcipenic Rickets Vitamin D deficient ( Nutritional) Rickets Vitamin D dependent Rickets • Type I • Type II Phosphopenic Rickets Hereditary • • • • X-linked Hypophosphatemia(vitamin D-Resistant Rickets) Autosomal Dominant Autosomal Recessive Hypophosphatemic rickets with hypercalciuria Acquired disorder • Tumor-induced (or oncogenic) osteomalacia Clinical Features Skeletal findings • • • • • • • Delayed closure of fontanelles Parietal and frontal bossing Craniotabes (soft skull bones) Rachitic rosary Harrison Grove Widening of epiphyseal plate Progressive lateral bowing of the femur and tibia Radiological • Disorganization of the growth plate with cupping, splaying, cortical spurs, stippling. • Cupping of metaphysis • Looser zones/pseudofractures • Osteopenia Lab Findings Calcipenic rickets Phosphopenic rickets Serum Phosphate Decreased Decreased Serum Calcium Decreased Or Normal Normal ALP Raised Raised PTH Increased Normal Vitamin D Low Or Normal Normal TRP Reduced Reduced TmP/GFR Reduced Reduced FGF23 Increased Q 2. Following is the bone profile of a technologist working in your laboratory who fractured her ankle because of a minor trauma in the laboratory. • Calcium: 7.2 mg/dl • Albumin : 4 g/dl • Phosphorous: 5.47 mg/dl • PTH: 5 pg/ml The lab investigation you would like to request next would be: a. 25-hydroxy vitamin D b. Alkaline phosphatase c. Creatinine d. Magnesium e. N-Telopeptide d. Magnesium Regulation of PTH Secretion • Secretion of PTH is controlled chiefly by serum [Ca2+] through negative feedback • Calcium-sensing receptors located on parathyroid cells are activated when [Ca2+] is elevated • The G-protein coupled calcium receptors bind extracellular calcium • High concentrations of extracellular calcium result in activation of the Gq G-protein coupled cascade through the action of phospholipase C • This hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to liberate intracellular messengers IP3 and diacylglycerol (DAG) Regulation of PTH Secretion • These two messengers result in a release of calcium from intracellular stores and a subsequent flux of extracellular calcium into the cytoplasmic space • This results in an intracellular Ca concentration that inhibits the secretion of preformed PTH from storage granules in the gland • In contrast to the mechanism that most secretory cells use, calcium inhibits vesicle fusion and release of PTH. In the parathyroids, magnesium serves this role in stimulus-secretion coupling • Hypomagnesemia inhibits PTH secretion and also causes resistance to PTH, leading to a form of hypoparathyroidism that is reversible • Hypermagnesemia also results in inhibition of PTH secretion Parathyroid Stimulators • Decreased serum [Ca2+] • Mild decreases in serum [Mg2+] • An increase in serum phosphate (increased phosphate causes it to complex with serum calcium, forming calcium phosphate, which reduces stimulation of Ca-sensitive receptors (CaSr) that do not sense calcium phosphate, triggering an increase in PTH) Parathyroid Inhibitors • Increased serum [Ca2+]. • Severe decreases in serum [Mg2+], which also produces symptoms of hypoparathyroidism (such as hypocalcemia) • Calcitriol Regulation of PTH • • • • • • • Ca binds to CaSR extracellular domain Conformational changes Interaction with G protein Gqa activates phospholipase C Intracellular Ca altered Hydrolysis of phospatidyl inositol 4 5 bisphosphate Inositol 3 phosphate inhibits PTH release Q. 3: A 52-year-old woman with menopause at 42 years of age was being evaluated by a physician for fracture risk. She fractured her ankle while getting off a rickshaw 8 months previously. DXA scan showed her T score at the hip was -2.3. Her mother had fractured her hip at the age of 63. She dislikes dairy products and smokes occasionally. The most significant risk factor for her fracture risk, independent of her bone mineral density reading is: a. Early menopause b. Low calcium intake c. Osteoporosis in mother d. Previous fracture e. Smoking d. Previous Fracture Osteoporosis A disease characterized by: • low bone mass • microarchitectural deterioration of the bone tissue Leading to: • enhanced bone fragility • increase in fracture risk Fractures • Fractures are the most dangerous aspect of osteoporosis • Debilitating acute and chronic pain in the elderly is often attributed to fractures from osteoporosis and can lead to further disability and early mortality • These fractures may also be asymptomatic • The most common osteoporotic fractures are of the wrist, spine, shoulder and hip Fragility fracture • Type of pathologic fracture that occurs as result of normal activities, such as a fall from standing height or less. • There are 3 fracture sites said to be typical of fragility fractures: vertebral fractures, fractures of the neck of the femur, and Colles fracture of the wrist. • This definition arises because a normal human being ought to be able to fall from standing height without breaking any bones, and a fracture therefore suggests weakness of the skeleton. Clinical risk categories for osteoporosis and osteoporotic fractures Extremely high risk • Prior osteoporotic fracture (without significant trauma) • Glucocorticosteroid use (prednisone ≥7.5 mg/d or equivalent for ≥6 months) • Solid organ transplant (pre or post, especially in first 2-3 years) High risk • Glucocorticosteroid use (prednisone ≥5 mg/day or equivalent, for ≥3 months) • Woman age >65 yrs /man age >70 yrs • Postmenopausal woman or older man with one or more of: Personal history of low impact fracture Family history of fracture hip, wrist, or spine (first degree relative age ≥50 yrs) Currently smoking Rheumatoid arthritis BMI <20 Recent weight loss <10% Multiple risk factors for falling Clinical risk categories for osteoporosis and osteoporotic fractures Moderate risk • Hormonal conditions • Hypogonadism • Late menarche (age >15 yrs) • Early menopause (age <45 yrs) • Cushing's syndrome • Hyperparathyroidism (primary or secondary) • Thyrotoxicosis • Gastrointestinal and nutritional factors • Gastrectomy • Low gastric acid • • • • Celiac disease Bariatric surgery Inflammatory bowel disease Pancreatic insufficiency • Heavy alcohol use • Family history of osteoporosis Q.4: A 47-year-old female is noted to have a serum calcium level of 11.1 mg/dL (2.75 mmol/L) with normal creatinine at the time of a routine annual visit. Investigations on follow-up after 1 month shows: • Calcium: • 25 hydroxy vitamin D 63 ng/ml • Parathyroid hormone 125 pg/ml 11 mg/dL (Ref Value for normal >30 ng/ml) (16-87 pg/ml) The most likely cause of hypercalcemia is: a. b. c. d. e. Humoral hypercalcemia of malignancy Primary hyperparathyroidism Secondary hyperparathyroidism Tertiary hyperparathyroidism Vitamin D toxicity b. Primary hyperparathyroidism Hyperparathyroidism Primary Secondary Overproduction of PTH secondary to a chronic abnormal stimulus for its production Tertiary Definition Unregulated overproduction of PTH resulting in abnormal calcium homeostasis Cause Adenoma CKD 5 Familial (MEN 1/ MEN2) Vit D deficiency Malabsorption Prolonged secondary hyperparathyroidism Long standing CKD LABS Raised Ca Raised PTH Low P Mild-to-mod increase in 24-hour urinary Ca excretion Raised Ca Raised PTH P often raised Vitamin D normal Low-normal Ca Raised PTH P levels depend on aetiology (eg, high in CKD, low in VDD) Excessive secretion of PTH after longstanding secondary hyperparathyroidism (low vitamin D or CKD) Effects of high PTH • Increases the release of calcium from bone matrix • Increases calcium reabsorption by the kidney • Increases phosphate excretion • Increases renal production of 1,25dihydroxyvitamin D3 (calcitriol), which increases intestinal absorption of calcium Q. 5: Blood sample of parathyroid hormone (PTH) is transported in ice because its half-life is: a. b. c. d. e. 20 seconds 30 seconds 2-4 min 8-10 min 15 min c. 2-4 min PTH molecule • Linear peptide consisting of 84 amino acids • PTH present in circulation is very heterogeneous • Heterogeneity is the consequence of a complex metabolism that starts in the parathyroid cells and continues in other tissues, mainly in the kidneys and liver • A circulation pool of “PTH peptides,” not only in pathological conditions, but also in normal individuals PTH assays: Evolution • In the first gen, noncompetitive, “sandwich” type assay, a single polyclonal antibody competes for labeled PTH and the serum forms • In the 2nd-gen assays, immunometric, 2 distinct antibodies (usually monoclonal), directed against different epitopes, bind the PTH forms present in the sample. One of the antibodies is bound to a solid phase, and the other is labeled • In the third gen assays, the recognition is based on other principles (mass spectrometry) in serum samples previously purified Immunometric assays a breakthrough • Recognition of PTH by two different antibodies, one carboxyl terminal and the other amino terminal • Widely available • Adapted to most of the automation platforms • Specificity of the amino terminal antibody defines if the assay measures only the bioactive PTH circulating form (including the first amino terminal amino acids) or the “intact” PTH, which includes, besides bioactive PTH, other “long” carboxyl-terminal forms, for example, 7–84-PTH • Assays for “intact” PTH are the most commonly available and the potential advantage of the bioactive PTH assays is still debatable PTH Half Life • The native or intact (1-84) PTH has a short half-life, 2-4 minutes • Whereas the carboxy and midmolecule fragments, which are biologically inactive, have half-lives 10- to 20-fold higher. • The high concentrations of biologically inactive fragments have interfered with use of C-terminal or midmolecule assays for evaluation of parathyroid function in patients with impaired renal function. PTH Half Life (Cont) • Intact PTH assays provide a more accurate assessment of parathyroid patients including those with various renal diseases. • ESRD: predominance of the carboxyl terminal ones, are present in great quantities in comparison to the intact 1–84 form Q. 6: A 65-year-old female, complains of nausea, lethargy and bone pains for last 8-10 months. The investigations on admission showed: • Serum Calcium 7.2 mg/dl • Serum Albumin 2.9 g/dL The corrected calcium (mg/dl) is: a. b. c. d. e. 7.56 7.81 8.08 8.29 8.37 c. 8.08 Corrected Calcium • One can derive a corrected Ca (adjusted Ca) level, to allow for the change in total calcium due to the change in albumin-bound calcium • Gives an estimate of what the total calcium level would be if the albumin were a specified normal value • Each 1 g/dL decrease of albumin will decrease 0.8 mg/dL in measured serum Ca and thus 0.8 must be added to the measured Ca to get a corrected Ca value Formula for Corrected Calcium • Corrected calcium (mg/dL) = measured total Ca (mg/dL) + 0.8 (4.0 - serum albumin [g/dL]), where 4.0 represents the average albumin level in g/dL. • Corrected calcium (mmol/L) = measured total Ca (mmol/L) + 0.02 (40 - serum albumin [g/L]), where 40 represents the average albumin level in g/L Q. 7: A 55-year-old man with recurrent bone pains was evaluated in a bone clinic. Following laboratory investigations were done: • Serum creatinine: 0.5 mg/dl • Serum phosphate: 1.2 mg/dl • Serum calcium: 8.6 mg/dl • Urinary phosphate: 340 mg/dl • Urinary creatinine: 55 mg/dl The TMP- GFR (mg/dl) of this man is: a. 0.25 b. 0.06 c. 0.05 d. -0.25 e. -1.88 e. -1.88 Formula for TMP/GFR • Tubular reabsorption of phosphate (TRP) • Tubular maximal reabsorption rate of phosphate to GFR (TmP/GFR) Q. 8: Following is the biochemical bone profile of a 55-year-old man during routine annual checkup. Bone X-ray was normal. He also gave history of recurrent kidney stones since last 3 years. His biochemical results showed: • Serum Na: 141 mmol/L • Serum K: 3.8 mmol/L • Serum Chloride: 111 mmol/L • Blood Ionized Ca: 3.2 mmol/L • Serum P: 0.86 mmol/L • Serum ALP: 80 U/L • Creatinine: 0.9 mg/dl Investigation which would help in confirming your diagnosis in blood is: a. 25-hydroxyvitamin D b. FGF-23 c. Magnesium d. N-telopeptide of type I collagen e. Parathyroid hormone e. Parathyroid Hormone Q. 9: If the Parathyroid hormone is undetectable which panel of laboratory investigations will help you make the diagnosis? a. b. c. d. e. 25OHD, PTH-rp , ACE 25OHD, PTH-rp, NTX Ca, ACE, ALP Ca, P, 25OHD P, PTH-rp, ALP e. Ca, P, 25OHD Identify the mystery molecules! Match the picture to the correct option: 10.1.c NTX 10.2. d. Parathyroid hormone 10.3.b. Bisphosphonate 10.4.e. Telopeptide cross links 10.5.a.1, 25 dihydroxy-vitamin D3 Part II Short Answer Questions: Q.11: A 5 year old girl is brought to a paediatrician for not being able to walk properly since one and a half year. Mother explained that her marriage was consanguineous and two of her boys (10 years and 8 years old) had deformed bones and were unable to walk. On examination, there are skeletal deformities of both upper and lower limbs, frontal bossing and pallor. Her extremities have widened wrists and ankles. The laboratory evaluation included: Serum • Creatinine 0.5 mg/dl • Calcium 8.4 mg/dl • Phosphorus 1.8 mg/dl • Alkaline phosphatase 1917 U/l • 25OHD 28 ng/ml (Ref Value for normal >30 ng/ml) • PTH 90 pg/ml Urine • Urinary phosphate 740 mg/day X-ray of wrist and legs was requested: The paediatrician wanted to confirm his suspicion and ordered TMP-GFR in this patient. a. Which disease is the paediatrician suspecting and why did he order TmP-GFR? • Hypophosphatemic rickets or vitamin D resistant or X linked Hypophosphatemic rickets • XLH usually presents with typical signs of rickets in young children, accompanied by hypophosphatemia and low TmP/GFR hence TmP/GFR will confirm his suspicion b. How TmP-GFR is calculated? • This calculation is used to estimate the ratio of phosphorus tubule maximum (TmP) to glomerular filtration rate (GFR). Fraction Excretion of P (FEPO4)= UPO4 /PPO4 / Ucreat /Pcreat 1 - FEPO4 = TRP Assuming PPO4 = [PO4]GFR TmPO4/GFR = TRP X PPO4 TmP/GFR The ratio of renal tubular maximum reabsorption rate of phosphate to the glomerular filtration rate TmP/GFR is used to 1. Diagnose: • • • 2. XLH Hereditary hypophosphataemic rickets with hypercalciuria Oncogenic osteomalacia Indicate the need for phosphate replacement and extent of its intracellular repletion. 3. Monitor recovery of renal tubular function after Damage Calculation of TmP/GFR TRP=1-{(UP/Pp)×(Pcr/Ucr)} If TRP =/< 0.86 then TMP/GFR = TRP × Pp If TRP > 0.86 then TMP/GFR= 0.3×TRP/{1-(0.8×TRP)}× Pp Where TRP= fractional tubular reabsorption of phosphate UP =Urinary Phosphate Pp =Serum Phophate Pcr = Serum Creatnine Ucr= Urinary Creatnine Interpretation of TmP/GFR Interpretation: Dependent upon clinical situation. Interpreted in conjunction with the serum phosphorous TMP/GFR is reduced in: XLH • primary hyperparathyroidism • renal tubular disorder • osteomalacia. • Increased in: • Children • Hypoparathyroidism. c. How will you interpret the result of TMP/GFR in diagnosing this child? • TMP/GFR if low: confirms Hypophosphatemic rickets and vice versa d. Enlist possible findings in the bones (physical examination and radiological) you may find in such patients. • • • • • • • • • Disproportionate short stature Delayed dentition Dental absecces Extrasekeltal calcification of tendons, ligaments, capsules Craniosyntostosis Rachitic rosary ribs Cupping of ribs Fraying and flaying of radius Genu varum (bowed legs) Enumerate tests/assays which are essential for the diagnosis of this disease. e. • • • • • • • • • Serum P Serum Ca Serum ALP Serum PTH Serum 25 OHD Serum FGF23 TmP-GFR Urinary Calcium PHEX gene analysis (if there) Q.12: A five and a half month old boy was brought to a pediatric clinic by his mother. His mother told the doctor that she noticed that her boy had difficulty in breathing since few months. On examination he was not in acute distress, the boy’s chest had prominent nodules on the costochondral junction and closed anterior and posterior fontanelles. Upon follow-up, laboratory tests showed: • Ionised calcium: 7.5 mg/dl • Serum phosphate: 2.4 mg/dl • Alkaline phosphatase : 22 U/L • X-ray wrist: widened metaphysis with osteopenia a. What is the diagnosis? • Hypophosphatasia Hypophosphatasia • Variable inheritance • Mutation in liver/bone/kidney alkaline phosphatase gene encoding the tissue non specific alkaline phosphatase • Diagnosis is done by biochemical analysis and sequencing of ALP gene • Serum ALP markedly reduced • Elevated urinary phosphoethanolamine • Elevated pyridoxal 5 phosphate Signs and Symptoms • • • • • • • • • • • • Vary widely Can appear anywhere from before birth to adulthood The most severe forms of the disorder tend to occur before birth and in early infancy Weakens/softens the bones Skeletal abnormalities similar to rickets Short limbs Abnormally shaped chest Soft skull bones Poor feeding Failure to gain weight Respiratory problems High levels of calcium in the blood How common is hypophosphatasia? • Severe forms of hypophosphatasia affect an estimated 1 in 100,000 newborns • Milder cases, such as those that appear in childhood or adulthood, probably occur more frequently • This condition appears to be most common in Caucasian (white) populations • It is particularly frequent in a Mennonite population in Manitoba, Canada, where about 1 in 2,500 infants is born with severe features of the condition b. Name the pathognomic finding present in this patient which supports your diagnosis in this patient. • Low Alkaline Phosphatase c. What is the type of inheritance of this disease? • Variable • AD • AR d. What are the different forms of this disease that are recognized? • • • • • • Perinatal lethal Prenatal benign Infantile Childhood Adult Odonto hypophosphatasia e. The boy’s mother is pregnant and would like her baby in the womb to be tested for the disease. Which investigation will you suggest? • Mutation analysis of chorionic villous DNAs Q. 13: A 65 years male known hypertensive and diabetic since last 20 years has extreme bone pains. On examination he has puffiness under his eyes and pedal edema. He has the following biochemical profile: • Serum Calcium: 8.2 mg/dl • Serum Urea: 191 mg/dl • Serum Phosphorus: 5.3 mg/dl • PTH: 211 pg/ml • Serum albumin 3.0 g/dl a. What is the most probable cause of the biochemical findings? • Chronic kidney disease (+Metabolic Bone Disease) b. What further laboratory investigations would you like to request and why? • Serum creatinine to calculate eGFR • 25 hydroxy Vitamin D levels: the only barometer to know VD status. It is imp to measure it as PTH is high. Plan is to replace it if less than 30 ng/m, • 1, 25 dihydroxy Vitamin D if available in your lab • Baseline alkaline phosphatase has a prognostic implication towards bone involvement, marker for bone osteodystrophy in CKD c. He was referred for dietary counseling because of the serum phosphorous levels noted. How would the nutritionist assist him? • Low intake of P in diet • Limit dietary P • Understand high P content food (milk and cheese, dried beans, peas, colas, canned iced teas, lemonade, nuts, and peanut butter, chapati) • Low P alternatives :Liquid non-dairy creamer,Cooked rice, cereals,Popcorn,Peas Lemon-lime soda, Powdered iced tea and lemonade mixes • Add phosphate binders d. What could be the role of FGF-23 in such patients? • FGF23 correlates with decline in GFR • FGF23 correlates with elevated phosphate FGF-23 • Recently, role of phosphatanin has evolved in phosphate and vitamin D homeostasis • Many phosphotanins have been described; however role of Fibroblast Growth Factor 23 (FGF23), which is an osteocytederived hormone, has been studied recently in regulation of phosphate and vitamin D homeostasis • FGF23 reduces serum 1,25(OH)2D level by suppressing the expression of 25OHD-1α hydroxylase and also enhancing the expression of 25OHD-24-hydroxylase CKD and FGF-23 • It has become increasingly clear that P metabolism plays a critical role in the pathophysiology in CKD • Hyperphosphataemia should be aggressively treated to improve life expectancy of CKD patients • In addition to traditional cardiovascular risk factors, disturbances in calcium-phosphate metabolism are regarded as strong contributing factors of higher cardiovascular mortality in CKD patients e. What will be the therapeutic goals and challenges in this patient? Many challenges but 4 imp ones are: • Normalize calcium and keep it in the range • Reducing P levels and keep it in the range • Evaluate Vit D deficiency and replace it • Lower PTH by treating with calcitriol or vitamin D analogs • Reference: KDIGO Q. 14: A 49-year-old woman, presents to metabolic bone physician with complaints of severe knee pain. She is married with 3 children. She does try to go on walks with her family and neighbors on and off. She was diagnosed as having rheumatoid arthritis 7 years ago and since then is on steroids. She does not smoke or drink. She completed her transition to post menopause about 10 years ago and has never used any hormones for menopause. Her father fractured his hip in a minor fall at the age of 70 years. Her general physical examination showed: • Height: 5'4", • Weight: 203 lb, • BP: 119/78 mmHg, • Pulse: 70 beats/min, • Respiratory rate: 12 breaths/min a. Name the risk factors for osteoporosis and fracture present in this patient which indicate osteoporosis screening by DXA scan? • • • • • Rheumatoid arthritis Steroids Premature menopause Family history of low impact fracture Weight Bone Mass by Age and Sex Pathogenesis of Estrogen Deficiency and Bone Loss Estrogen loss triggers increases in IL-1, IL-6, and TNF due to: • Reduced suppression of gene transcription of IL-6 and TNF • Increased number of monocytes • Increased cytokines lead to increased osteoclast development and lifespan She underwent a DXA scan, which revealed spine and femoral neck BMD T-scores of -1.5 and -2.9, respectively. b. How will you interpret the DXA scan report according to WHO Diagnostic Categories for Osteoporosis and Low Bone Mass? • Osteopenia: BMD between -1.0 and – 2.5 SD below the norm for young healthy adult of same sex (T score < 1.0 and > - 2.5). • Osteoporosis: BMD – 2.5 SD or below (T score < - 2.5) In this Patient • Spine : osteopenia • Femoral neck : severe osteoporosis BMD testing • The definition of osteoporosis developed for World Health Organization (WHO) is based on bone densitometry • Normal bone mass is defined as BMD above or below 1 standard deviation (SD) from the premenopausal mean value (T-score), osteopenia as BMD below -1SD but above -2.5 SD and osteoporosis as BMD below -2.5 SD DXA • Non-invasive • Takes only 10-15 minutes, and exposes patients to only a small amount of radiation (less than one tenth of the amount of a chest x-ray) • do not provide any information about bone architecture • Screening for osteoporosis should be performed with BMD testing by DXA if available, and not more frequently than every 2 years. (Ref: ACPM 2009) DXA for Pakistanis • Availability and access to DXA machines is an issue in Pakistan • There were only 16 DXA machines across Pakistan as reported by IOF in 2007 • This number has risen but there is need of increasing this more especially in public care settings • The expense of DXA scans makes them unavailable for the majority even if the machine is made accessible (average cost of DXA being ~PKR 3500) c. What laboratory investigations will you order to exclude secondary causes of osteoporosis? • • • • • • • TSH PTH HbA1C/glucose Urinary cortisol/ ACTH Creatinine Autoimmune Antibody panel FSH, LH, Testosterone, estrogen Secondary Osteoporosis Slides courtesy of Dr Sabiha Waseem, Canada Causes of Secondary Osteoporosis Endocrine or metabolic causes Rheumatological Hematologic diseases diseases • Diabetes mellitus • Rheumatoid • Myeloma (type 1) arthritis • Monoclonal • Acromegaly • Ankylosing gammopathy of • GH deficiency (rare) spondylitis undetermined • Athletic amenorrhea • Systemic lupus significance • Premature menopause erythematosus • Lymphoma/leukemi • Hemochromatosis a • Hyperadrenocorticism • Systemic • Hyperparathyroidism mastocytosis (rare) • Hyperprolactinemia • Disseminated • Thyrotoxicosis carcinoma • Chemotherapy Collagen/genetic disorders • Ehlers-Danlos syndrome • Glycogen storage diseases • Homocystinuria • Hypophosphatasia • Marfan syndrome • Osteogenesis imperfecta Causes of Secondary Osteoporosis (cont) Medications • • • • • • • • • • Cyclosporine (Sandimmune) Excess thyroid hormone Glucocorticoids GnRH agonists Methotrexate (Rheumatrex) Phenobarbital Phenothiazines Phenytoin (Dilantin) Heparin, prolonged treatment Proton pump inhibitors, prolonged treatment Nutritional • • • • Anorexia nervosa Alcoholism Calcium deficiency Chronic liver disease, Liver cirrhosis, Chronic biliary tract obstruction • Gastric operations (Gastrectomy) • Malabsorption syndromes, celiac disease, IBD • Vitamin D deficiency Diagnostic tests in the work-up of secondary osteoporosis. Diagnostic test • History and physical exam Purpose • To identify risk factors for fractures, the underlying disease, and potential drugs • Dual-energy X-ray absorptiometry (lumbar spine and • To quantify bone mineral density hip) • To detect prevalent vertebral fractures • Spinal X-rays • To exclude osteolytic lesions or tumors d. Using FRAX what is the ten year probability of fracture (%) in her? • 3.7 % major osteoporotic • 0.3% hip fracture (Using WHO FRAX Indian version) Fracture Risk Assessment Tools • Qualitatively predict the 10-year fracture probability of hip and major osteoporosis related fractures and can be used to define cost effective intervention strategies for primary and secondary fracture prevention Various Tools :Most of these are based on non-Asian population • • • • • • • • • • • WHO Fracture Risk Assessment Tool (FRAX) Garvan Institute fracture risk calculator (Garvan) Q fracture Scores (Qfracture) Simple calculated osteoporosis risk estimation (SCORE) Age, BOdy size, No Estrogen (ABONE) OSteoporosis Index of RISk (OSIRIS) Study of Osteoporosis Fractures-Study Utilizing Risk Factors (SOFSURF) Osteoporosis self-assessment tool (OST) National Osteoporosis Foundation (NOF) guidelines Weight-Only–EPIDOS (WO-E) Osteoporosis Risk Assessment Instrument (ORAI) No Tool in Pakistan • Unfortunately no such tool is available for Pakistan where the risk factors are different from the Caucasians • Osteoporosis screening questionnaires have thus far not been validated in Pakistani community • However, a new version of FRAX is available which can calculated fracture probability for 26 countries • Data from Singapore, which is a multi-ethnic country, is also represented on the FRAX tool • The calculator provides separate data for Chinese, Malay and Indian population of Singapore • The Singapore, Indian data can easily be extrapolated to the population living in India or neighboring countries. e. Name the group of medicines most commonly prescribed in such patients. • Calcium supplements • Vitamin D • Bisphosphonates Alendronate (Fosamax) Risedronate (Actonel) Ibandronate (Boniva) Zoledronic acid (Reclast) • Hormone Replacement Therapy Thank You and Best Of Luck